Healthcare Companies Receive Approvals, Recognitions, Agreements, and Announce Senior Level Appointments- Analyst Notes on

Healthcare Companies Receive Approvals, Recognitions, Agreements, and Announce
    Senior Level Appointments- Analyst Notes on Pfizer, Boston Scientific,
                         WellPoint, Aetna, and Humana

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 18, 2014

NEW YORK, March 18, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Pfizer Inc.
(NYSE: PFE), Boston Scientific Corporation (NYSE: BSX), WellPoint Inc. (NYSE:
WLP), Aetna Inc. (NYSE: AET), and Humana Inc. (NYSE: HUM). Private wealth
members receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register

PfizerInc.AnalystNotes

On March 12, 2014, Pfizer Inc. (Pfizer) issued a press release confirming that
the United States District Court for the Eastern District of Virginia granted
summary judgment invalidating the reissue patent (U.S. Patent No. RE44, 048),
covering methods of treating osteoarthritis and other approved conditions with
celecoxib, the active ingredient in Celebrex®. According to the press release,
the Company disagrees with the ruling and will pursue all available remedies
including an immediate appeal of the court's decision. Additionally, Pfizer
stated that a trial was scheduled to begin on March 19, 2014 for infringement
of the reissue patent in the action brought by Pfizer against a few generic
companies. These generic companies had previously filed an abbreviated new
drug application with the US FDA seeking approval to market a generic form of
celecoxib in the US beginning on May 30, 2014, when Pfizer's basic Celebrex®
compound patent (including the six-month pediatric exclusivity period)expires.
The full analyst notes on Pfizer Inc. are available to download free of charge
at:

http://www.AnalystsReview.com/03182014/PFE/report.pdf

BostonScientificCorporationAnalystNotes

On March 12, 2014, Boston Scientific Corporation (Boston Scientific) announced
that it has received CE Mark approval for the REBEL™ Platinum Chromium
Coronary Stent System, the Company's last generation bare metal stent for the
treatment of coronary artery disease (CAD). Kevin Ballinger, President,
Interventional Cardiology, Boston Scientific stated, "Boston Scientific is
committed to advancing cardiology and providing the best treatment options for
all patients with coronary artery disease. This includes innovating and
improving the performance of bare metal stent technology to enhance patient
outcomes." The full analyst notes on Boston Scientific Corporation are
available to download free of charge at:

http://www.AnalystsReview.com/03182014/BSX/report.pdf

WellPointInc.AnalystNotes

On March 11, 2014, WellPoint Inc. (WellPoint) announced that the Company has
won a Bronze Stevie Award in the Sales Training or Coaching Program of the
Year category in the
8thAnnualStevieAwardsforSales&CustomerService. According to
WellPoint, the Bronze Stevie Award recognizes the Company's eight-week
CompassNewHireProgram for reinforcing foundational selling skills.
Commenting on the honor, Ken Goulet, Executive Vice President, President,
Commercial and Specialty Business, WellPoint, stated, "Our sales training
program for new hires is top-notch, and helped contribute to significant
growth in our commercial and specialty membership in January 2014. Being
recognized as a Stevie Award winner is a well-deserved honor for our sales
training teams." The full analyst notes on WellPoint Inc. are available to
download free of charge at:

http://www.AnalystsReview.com/03182014/WLP/report.pdf

AetnaInc.AnalystNotes

On March 11, 2014, Aetna Inc. (Aetna) along with Atlantic Accountable Care
Organization (Atlantic ACO), a partner of Atlantic Health System, announced a
new accountable care agreement that will improve the coordination and delivery
of patient care. According to the Company, Aetna members who use the Atlantic
ACO and Centers of Excellence will experience more coordinated care,
particularly those patients with chronic and complex conditions. Additionally,
the Company stated that Aetna members will also have enhanced access to
appropriate care and will benefit from the improved flow of information to
treating physicians in the Atlantic ACO. "Aetna will work closely with the ACO
physicians to identify specific areas where we can either develop or improve
on the sharing of specific, useful health information. In turn, the physicians
will use this information to improve care for patients, close gaps in care and
reduce waste. We are creating a continuous loop of improved information to
drive better care. By working together, we can bring better health, better
care and better cost to thousands of Aetna members beginning this spring,"
said John Lawrence, President of Aetna. The full analyst notes on Aetna Inc.
are available to download free of charge at:

http://www.AnalystsReview.com/03182014/AET/report.pdf

HumanaInc.AnalystNotes

On March 6, 2014, Humana Inc. (Humana) announced that it has appointed
Christopher Kay, as Senior Vice President and Chief Innovation Officer,
effective March 17, 2014. According to Humana, Kay will report to President
and CEO Bruce Broussard and will also serve on the Company's Management Team.
Additionally, Humana stated that Kay will lead the Company's innovation
strategy and will focus on innovations in personalized health designed to
simplify the health care experience, leading to better health outcomes.
Commenting on the appointment, Broussard stated, "Chris is a keen innovator
with a passion for creating new businesses in large organizations, and for
launching products and services that enhance the consumer experience. He
brings a wealth of experience in consumer-facing industries to a pivotal role
that is vital to Humana's future success." The full analyst notes on Humana
Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/HUM/report.pdf

AboutAnalystsReview

We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITORNOTES:

  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
    AnalystsReview.com.
  oForanyurgentconcernsorinquiries, please contact us at compliance
    [at] AnalystsReview.com.
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at]
    AnalystsReview.com for consideration.

COMPLIANCEPROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOTFINANCIALADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.

NOWARRANTYORLIABILITYASSUMED

Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review

Contact: Contact: Adam Redford, +852-8191-3972
 
Press spacebar to pause and continue. Press esc to stop.